FDA Determines Regulatory Review Period for INTEGRA Artificial Skin Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for INTEGRA Artificial Skin, a medical device, in accordance with patent extension regulations, following a submission to the US Department of Commerce for patent extension.